A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended
Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the
RP2D will be evaluated in phase 2 in patients with solid tumors of neuroendocrine
differentiation.